Research programme: regenerative cell therapy - CellvationAlternative Names: CEVA 102
Latest Information Update: 07 Dec 2016
At a glance
- Originator Cellvation
- Class Cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain injuries
Most Recent Events
- 06 Dec 2016 Preclinical trials in Brain injuries in USA (Parenteral)